A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV ΔNS2 Δ1313 I1314L, Lot RSV#006A, Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age, RSV-Seronegative Infants and Children 6 to 24 Months of Age, and Infants 4 to 6 Months of Age
Latest Information Update: 17 Nov 2023
At a glance
- Drugs RSV/deltaNS2/delta1313/I1314L (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- 21 Mar 2023 Planned End Date changed from 30 Apr 2023 to 1 Oct 2025.
- 21 Mar 2023 Planned primary completion date changed from 31 Dec 2022 to 30 Apr 2023.
- 21 Mar 2023 Status changed from recruiting to active, no longer recruiting.